1. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021; 398:786–802.

2. Heerspink HJ, Cherney DZ, Groop PH, Matthieu C, Rossing P, Tuttle KR, et al. People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action. Lancet Diabetes Endocrinol. 2023; 11:536–40.

3. Popovic DS, Patoulias D, Gnudi L, Mantzoros CS. Diabetic kidney disease in type 1 diabetes: challenges and differences from type 2 diabetes. Metabolism. 2024; 151:155763.

4. Chen Y, Lee K, Ni Z, He JC. Diabetic kidney disease: challenges, advances, and opportunities. Kidney Dis (Basel). 2020; 6:215–25.

5. Verges B. Cardiovascular disease in type 1 diabetes, an underestimated danger: epidemiological and pathophysiological data. Atherosclerosis. 2024; 394:117158.

6. Bakris GL, Molitch M. Are all patients with type 1 diabetes destined for dialysis if they live long enough?: probably not. Diabetes Care. 2018; 41:389–90.

7. de Boer IH, Bakris GL. Diabetic kidney disease: a determinant of cardiovascular risk in type 1 diabetes. Diabetes Care. 2018; 41:662–3.

8. Gong B, Yang W, Xing Y, Lai Y, Shan Z. Global, regional, and national burden of type 1 diabetes in adolescents and young adults. Pediatr Res. 2024; Mar. 5. [Epub].
https://doi.org/10.1038/s41390-024-03107-5.

9. Francis A, Harhay MN, Ong AC, Tummalapalli SL, Ortiz A, Fogo AB, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024; 20:473–85.

10. Lawrence JM, Yi-Frazier JP, Black MH, Anderson A, Hood K, Imperatore G, et al. Demographic and clinical correlates of diabetes-related quality of life among youth with type 1 diabetes. J Pediatr. 2012; 161:201–7.

11. Ma Z, He W, Zhou Y, Mai L, Xu L, Li C, et al. Global burden of stroke in adolescents and young adults (aged 15-39 years) from 1990 to 2019: a comprehensive trend analysis based on the global burden of disease study 2019. BMC Public Health. 2024; 24:2042.

12. Chao AM, Minges KE, Park C, Dumser S, Murphy KM, Grey M, et al. General life and diabetes-related stressors in early adolescents with type 1 diabetes. J Pediatr Health Care. 2016; 30:133–42.

13. Anderson BJ, Laffel LM, Domenger C, Danne T, Phillip M, Mazza C, et al. Factors associated with diabetes-specific health-related quality of life in youth with type 1 diabetes: the global TEENs study. Diabetes Care. 2017; 40:1002–9.

14. Bello AK, Okpechi IG, Levin A, Ye F, Damster S, Arruebo S, et al. An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health. 2024; 12:e382. –95.
15. GBD 2021 Forecasting Collaborators. Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403:2204–56.
16. Murray CJ; GBD 2021 Collaborators. Findings from the global burden of disease study 2021. Lancet. 2024; 403:2259–62.

17. Murray CJ. The global burden of disease study at 30 years. Nat Med. 2022; 28:2019–26.

18. GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403:2162–203.
19. GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disabilityadjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403:2133–61.
20. GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021. Lancet. 2024; 403:2100–32.
21. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020; 396:1204–22.
22. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000; 19:335–51.

23. Chen J, Li C, Bu CL, Wang Y, Qi M, Fu P, et al. Global burden of non-communicable diseases attributable to kidney dysfunction with projection into 2040. Chin Med J (Engl). 2024; May. 28. [Epub].
https://doi.org/10.1097/CM9.0000000000003143.

24. Baek JH, Lee WJ, Lee BW, Kim SK, Kim G, Jin SM, et al. Age at diagnosis and the risk of diabetic nephropathy in young patients with type 1 diabetes mellitus. Diabetes Metab J. 2021; 45:46–54.

25. Chan JC, O CK, Luk AO. Young-onset diabetes in east Asians: from epidemiology to precision medicine. Endocrinol Metab (Seoul). 2024; 39:239–54.

26. Weng J, Zhou Z, Guo L, Zhu D, Ji L, Luo X, et al. Incidence of type 1 diabetes in China, 2010-13: population based study. BMJ. 2018; 360:j5295.

27. Lipman TH, Levitt Katz LE, Ratcliffe SJ, Murphy KM, Aguilar A, Rezvani I, et al. Increasing incidence of type 1 diabetes in youth: twenty years of the Philadelphia pediatric diabetes registry. Diabetes Care. 2013; 36:1597–603.
28. Zorena K, Michalska M, Kurpas M, Jaskulak M, Murawska A, Rostami S. Environmental factors and the risk of developing type 1 diabetes: old disease and new data. Biology (Basel). 2022; 11:608.

29. Op de Beeck A, Eizirik DL. Viral infections in type 1 diabetes mellitus: why the β cells? Nat Rev Endocrinol. 2016; 12:263–73.

30. Patelarou E, Girvalaki C, Brokalaki H, Patelarou A, Androulaki Z, Vardavas C. Current evidence on the associations of breastfeeding, infant formula, and cow’s milk introduction with type 1 diabetes mellitus: a systematic review. Nutr Rev. 2012; 70:509–19.

31. Hill CJ, Cardwell CR, Maxwell AP, Young RJ, Matthews B, O’Donoghue DJ, et al. Obesity and kidney disease in type 1 and 2 diabetes: an analysis of the national diabetes audit. QJM. 2013; 106:933–42.

32. Wrzosek M, Wisniewska K, Sawicka A, Talalaj M, Nowicka G. Early onset of obesity and adult onset of obesity as factors affecting patient characteristics prior to bariatric surgery. Obes Surg. 2018; 28:3902–9.

33. Maric C. Sex, diabetes and the kidney. Am J Physiol Renal Physiol. 2009; 296:F680–8.

34. Giandalia A, Giuffrida AE, Gembillo G, Cucinotta D, Squadrito G, Santoro D, et al. Gender differences in diabetic kidney disease: focus on hormonal, genetic and clinical factors. Int J Mol Sci. 2021; 22:5808.

35. Mollsten A, Svensson M, Waernbaum I, Berhan Y, Schon S, Nystrom L, et al. Cumulative risk, age at onset, and sex-specific differences for developing end-stage renal disease in young patients with type 1 diabetes: a nationwide population-based cohort study. Diabetes. 2010; 59:1803–8.
36. Harjutsalo V, Maric C, Forsblom C, Thorn L, Waden J, Groop PH, et al. Sex-related differences in the long-term risk of microvascular complications by age at onset of type 1 diabetes. Diabetologia. 2011; 54:1992–9.

37. Deng Y, Li N, Wu Y, Wang M, Yang S, Zheng Y, et al. Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019. Front Endocrinol (Lausanne). 2021; 12:672350.

38. Manicardi V, Russo G, Napoli A, Torlone E, Li Volsi P, Giorda CB, et al. Gender-disparities in adults with type 1 diabetes: more than a quality of care issue: a cross-sectional observational study from the AMD annals initiative. PLoS One. 2016; 11:e0162960.

39. GBD 2019 Viewpoint Collaborators. Five insights from the global burden of disease study 2019. Lancet. 2020; 396:1135–59.
40. DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021; 17:319–34.

41. Neumiller JJ, Hirsch IB. Management of hyperglycemia in diabetic kidney disease. Diabetes Spectr. 2015; 28:214–9.

42. He L, Xue B, Wang B, Liu C, Gimeno Ruiz de Porras D, Delclos GL, et al. Impact of high, low, and non-optimum temperatures on chronic kidney disease in a changing climate, 1990-2019: a global analysis. Environ Res. 2022; 212(Pt A):113172.

43. Liu Y, Wen H, Bai J, Shi F, Bi R, Yu C. Burden of diabetes and kidney disease attributable to non-optimal temperature from 1990 to 2019: a systematic analysis from the global burden of disease study 2019. Sci Total Environ. 2022; 838(Pt 3):156495.

44. Morton GJ, Muta K, Kaiyala KJ, Rojas JM, Scarlett JM, Matsen ME, et al. Evidence that the sympathetic nervous system elicits rapid, coordinated, and reciprocal adjustments of insulin secretion and insulin sensitivity during cold exposure. Diabetes. 2017; 66:823–34.

45. Li Y, Lan L, Wang Y, Yang C, Tang W, Cui G, et al. Extremely cold and hot temperatures increase the risk of diabetes mortality in metropolitan areas of two Chinese cities. Environ Res. 2014; 134:91–7.

46. Vallianou NG, Geladari EV, Kounatidis D, Geladari CV, Stratigou T, Dourakis SP, et al. Diabetes mellitus in the era of climate change. Diabetes Metab. 2021; 47:101205.

47. Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022; 400:1788–801.
48. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380:2295–306.

49. Heerspink HJ, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020; 383:1436–46.
